Fig. 4
Effect of single or combined treatment with Anle 138b and PD03 on the motor disability and nigral neurodegeneration in PLP-α-syn mice. a Challenging beam test of PLP-α-syn mice receiving vehicle, PD03, Anle138b or combined PD03 + Anle138b treatment. One-way ANOVA followed by Bonferroni’s post-hoc test (**P < 0.01; ****P < 0.0001). b Immunohistochemistry of TH to identify dopaminergic neurons in the SNc of PLP-α-syn mice. c Number of TH-immunoreactive neurons in the SNc of PLP-α-syn mice receiving vehicle, PD03, Anle138b or combined PD03 + Anle138b treatment. One-way ANOVA followed by Bonferroni’s post-hoc test (***P < 0.001, *P < 0.05). d Total number of neurons in the SNc of PLP-α-syn mice counted in cresyl violet (CV) staining. One-way ANOVA followed by Bonferroni’s post-hoc test (***P < 0.001, **P < 0.01). e Linear regression analysis of correlations between dopaminergic neurons in the SNc and motor disability in the challenging beam test (R2 = 0.333, P = 0.0004)